IET Nanobiotechnology · 2017 · 67 citations · 70 references
PharmacyOncologyPharmacologyChemotherapyDrug DeliveryNanoparticle Drug DeliveryCancer Drug DeliveryCancer NanomedicineDrug EncapsulationNanomedicineNanoparticle Delivery SystemsNanoparticle FormulationsAnticancer ChemotherapyDrug Delivery NanocarriersIn Vivo StudiesLipid NanoparticlesNanoparticlesPolymer-lipid Hybrid NanocarriersSolid Lipid Nanoparticle EncapsulationSolubility
Over the past few years, taxanes have emerged as a new class of anticancer drugs. Docetaxel (DTX) the prototype of this class has been approved for the treatment of broad range of cancers. However, to date the commercial preparation of DTX (Taxotere ® ) is accompanying adverse side effects, intolerance, and poor solubility, which can be overcome by encapsulating them using solid lipid nanoparticles (SLNs). SLNs represent versatile delivery system of drugs with newer forms such as polymer–solid lipid hybrid, surface modified and long circulating nanoparticles bringing forth improved prospects for cancer chemotherapy. In this review, the authors have discussed the current uses of various SLNs formulations of DTX with key emphasis on controlled and site‐specific drug delivery along with enhanced antitumour activity elucidated via in vitro and in vivo studies. Furthermore, the review article highlights few approaches that can be used in combination with existing DTX‐loaded SLNs to supplement DTX drug delivery.
70
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text
Medicine, Oncology, Pharmacology +12